Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor

NCT ID: NCT00483093

Last Updated: 2014-05-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 22 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-07-31
• Study Completion Date: 2013-04-30

Brief Summary

The main objective of the trial is to document the safety of the combination (escalation doses of NGR-hTNF, from 0.2 mcg/sqm to 1.6 mcg/sqm , with a fixed dose of cisplatin, 80 mg/sqm). Safety will be established by clinical and laboratory assessment according to National Cancer Institute Common Toxicity Criteria (NCI-CTC ).

Detailed Description

This is a phase IB, open-label, non-randomized, dose-escalation study that will be conducted in sequential cohorts of patients. Three patients per each cohort are planned.

Patients, with advanced or metastatic solid tumor not amenable of standard therapy will be enrolled.

Conditions

Solid Tumors

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

A

Group Type: EXPERIMENTAL

NGR-hTNF

Intervention Type: DRUG

iv q3W escalating dose NGR-hTNF up to 1.6 mcg/sqm

Cisplatin

Intervention Type: DRUG

iv q3W 80 mg/sqm 30 minutes after NGR-hTNF infusion for a maximum of six cycles

Interventions

NGR-hTNF

iv q3W escalating dose NGR-hTNF up to 1.6 mcg/sqm

Intervention Type: DRUG

Cisplatin

iv q3W 80 mg/sqm 30 minutes after NGR-hTNF infusion for a maximum of six cycles

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients ≥18 years with advanced or metastatic solid tumor not amenable to any clinical improvement by current standard treatments and suitable for a treatment with cisplatin

• Life expectancy more than 3 months
• ECOG Performance status 0-1
• Absence of any conditions in which hypervolemia and its consequences (e.g. increased stroke volume, elevated blood pressure) may represent a risk for the patient
• Adequate baseline bone marrow, hepatic and renal function, defined as follows:
• Neutrophils > 1.5 x 10^9/L and platelets > 100 x 10^9/L
• Bilirubin < 1.5 x ULN
• AST and/or ALT < 2.5 x ULN in absence of liver metastasis
• AST and/or ALT < 5 x ULN in presence of liver metastasis
• Serum creatinine < 1.5 x ULN
• Creatinine clearance (estimated according to Cockcroft-Gault formula) ≥ 50 ml/min
• Patients may have had prior therapy providing the following conditions are met:
• Chemotherapy, radiation therapy, hormonal therapy or immunotherapy: wash-out period of 28 days
• Corticosteroid therapy wash out period of 14 days
• Surgery: wash-out period of 14 days
• Patients must give written informed consent to participate in the study

Exclusion Criteria

• Previous signs of severe toxicity platinum related
• Patients must not receive any other investigational agents while on study
• New York Heart Association class III or IV cardiac disease
• Unstable angina
• Patients with myocardial infarction within the last six (6) months
• Patient with significant peripheral vascular disease
• Clinical signs of CNS involvement
• Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol
• Known hypersensitivity/allergic reaction to human albumin preparations or to any of the excipients
• Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol
• Pregnancy or lactation. Patients - both males and females - with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AGC Biologics S.p.A.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Antonio Lambaise, MD

Role: STUDY_DIRECTOR

AGC Biologics S.p.A.

Locations

Fondazione San Raffaele del Monte Tabor

Milan, Milan,, Italy

Istituto Europeo Oncologico

Milan, Milan, Italy

Countries

Italy

References

Gregorc V, De Braud FG, De Pas TM, Scalamogna R, Citterio G, Milani A, Boselli S, Catania C, Donadoni G, Rossoni G, Ghio D, Spitaleri G, Ammannati C, Colombi S, Caligaris-Cappio F, Lambiase A, Bordignon C. Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors. Clin Cancer Res. 2011 Apr 1;17(7):1964-72. doi: 10.1158/1078-0432.CCR-10-1376. Epub 2011 Feb 9.

Reference Type: RESULT

PMID: 21307147 (View on PubMed)

Other Identifiers

2006-006035-42

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

NGR004

Identifier Type: -

Identifier Source: org_study_id